HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing.

Abstract
This double-blind, placebo-controlled study was designed to evaluate the efficacy and tolerability of early treatment of a single migraine attack, when headache pain was mild, with two doses (20 mg and 40 mg) of eletriptan. Patients (N = 613; female 79%; mean age 39 years) meeting International Headache Society criteria for migraine were encouraged, but not required, to utilize early treatment, thus providing an opportunity to assess the relative contribution to efficacy of pain severity and timing of dose. For the total patient sample (mild-to-severe headaches), 2-h pain-free rates were significantly higher than placebo (22%) on both eletriptan 20 mg (35%; P < 0.01) and eletriptan 40 mg (47%; P < 0.0001). For the cohort of patients who treated their headache when the pain intensity was mild, the 2-h pain-free rate on eletriptan 40 mg was 68% compared with 25% on placebo (P < 0.0001). Pain intensity at the time of taking eletriptan appeared to influence outcome more than the timing of the dose relative to headache onset. Eletriptan was well-tolerated, with adverse event rates similar to placebo when mild headaches were treated.
AuthorsJ L Brandes, D Kudrow, R Cady, P J Tiseo, W Sun, C R Sikes
JournalCephalalgia : an international journal of headache (Cephalalgia) Vol. 25 Issue 9 Pg. 735-42 (Sep 2005) ISSN: 0333-1024 [Print] England
PMID16109056 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Indoles
  • Pyrrolidines
  • Serotonin Receptor Agonists
  • Tryptamines
  • eletriptan
Topics
  • Adolescent
  • Adult
  • Aged
  • Female
  • Humans
  • Indoles (administration & dosage)
  • Male
  • Middle Aged
  • Migraine Disorders (drug therapy)
  • Pain (drug therapy)
  • Pyrrolidines (administration & dosage)
  • Serotonin Receptor Agonists (administration & dosage)
  • Time Factors
  • Treatment Outcome
  • Tryptamines

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: